The global aesthetic medicine market size was estimated at around USD 127.14 billion in 2023 and it is projected to hit around USD 511.67 billion by 2033, growing at a CAGR of 14.94% from 2024 to 2033.
The field of aesthetic medicine has experienced remarkable growth, propelled by evolving consumer preferences, advancements in technology, and an increasing emphasis on self-care and well-being. This burgeoning market encompasses a wide array of procedures and products aimed at enhancing physical appearance, boosting self-confidence, and promoting a sense of personal satisfaction.
The growth of the aesthetic medicine market is driven by an evolving societal attitude towards beauty and self-care have normalized cosmetic procedures, driving increased demand. Technological advancements have led to safer and more effective treatments, expanding the options available to patients. Additionally, globalization and social media influence have fueled the desire for flawless appearance, particularly among younger demographics. Rising disposable incomes, especially in emerging economies, have further boosted market growth by increasing accessibility to aesthetic treatments. However, regulatory challenges and ethical considerations remain important factors to navigate in ensuring sustained growth and maintaining trust within the industry.
The aesthetic medicine industry is segmented based on procedure type into invasive and non-invasive procedures. In 2023, the non-invasive procedures segment held the majority share of 56% in the market and is projected to experience the fastest growth rate throughout the forecast period. Factors such as minimal discomfort, immediate results, and affordability have fueled the global demand for non-invasive procedures. Common non-invasive treatments include Botox injections, soft tissue fillers, and chemical peels. Additionally, invasive procedures like liposuction, breast augmentation, and rhinoplasty remain popular choices among individuals seeking aesthetic enhancements. The increasing emphasis on physical appearance has contributed to the rising demand for these invasive procedures.
In 2023, North America commanded the largest share, accounting for 35% of the global aesthetic medicine market revenue. The region's robust healthcare infrastructure, widespread adoption of cosmetic procedures, increasing prevalence of skin disorders, and the presence of numerous certified and skilled cosmetic surgeons are key factors driving market growth in North America.
According to data from the International Society of Aesthetic Plastic Surgery (ISAPS) in 2022, the United States alone witnessed a significant number of aesthetic procedures, totaling 7,448,196. This highlights the enduring popularity and demand for aesthetic enhancements in the country, thereby propelling the U.S. aesthetic medicine market forward.
The Asia Pacific region is expected to exhibit the highest compound annual growth rate (CAGR) during the forecast period. This growth is fueled by countries such as China, India, Malaysia, and South Korea. Factors contributing to the region's growth include the availability of technologically advanced products and a growing emphasis on physical appearance. Furthermore, South Korea's reputation as a leading center for cosmetic surgeries serves as a significant driver for regional market expansion.
By Procedure
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Aesthetic Medicine Market
5.1. COVID-19 Landscape: Aesthetic Medicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Aesthetic Medicine Market, By Procedure
8.1.Aesthetic Medicine Market, by Procedure Type, 2024-2033
8.1.1. Invasive Procedures
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Non-invasive Procedures
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Aesthetic Medicine Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
Chapter 10. Company Profiles
10.1. AbbVie
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Cynosure
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Evolus Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Revance Galderma
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Lumenis
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Solta Medical
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Syneron Candela
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Alma Laser
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3.Financial Performance
10.8.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms